KTRA vs. CASI, NBRV, CARM, KRON, OCUP, AADI, LEXX, EYEN, IMRX, and LPCN
Should you be buying Kintara Therapeutics stock or one of its competitors? The main competitors of Kintara Therapeutics include CASI Pharmaceuticals (CASI), Nabriva Therapeutics (NBRV), Carisma Therapeutics (CARM), Kronos Bio (KRON), Ocuphire Pharma (OCUP), Aadi Bioscience (AADI), Lexaria Bioscience (LEXX), Eyenovia (EYEN), Immuneering (IMRX), and Lipocine (LPCN). These companies are all part of the "pharmaceutical preparations" industry.
CASI Pharmaceuticals (NASDAQ:CASI) and Kintara Therapeutics (NASDAQ:KTRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
Kintara Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Kintara Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CASI Pharmaceuticals and CASI Pharmaceuticals both had 1 articles in the media. Kintara Therapeutics' average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.
22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Kintara Therapeutics shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Kintara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
CASI Pharmaceuticals received 184 more outperform votes than Kintara Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Kintara Therapeutics an outperform vote while only 51.15% of users gave CASI Pharmaceuticals an outperform vote.
Kintara Therapeutics has a net margin of 0.00% compared to Kintara Therapeutics' net margin of -105.76%. CASI Pharmaceuticals' return on equity of 0.00% beat Kintara Therapeutics' return on equity.
CASI Pharmaceuticals presently has a consensus target price of $6.00, indicating a potential upside of 72.91%. Given Kintara Therapeutics' higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Kintara Therapeutics.
CASI Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Kintara Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
Summary
CASI Pharmaceuticals beats Kintara Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Kintara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kintara Therapeutics Competitors List
Related Companies and Tools
